Eagle Asset Management’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-16,815
| Closed | -$1.89M | – | 602 |
|
|
2023
Q3 | $1.89M | Sell |
16,815
-29,556
| -64% | -$3.75M | 0.01% | 440 |
|
|
2023
Q2 | $6.75M | Buy |
+46,371
| New | +$6.3M | 0.04% | 313 |
|
|
2022
Q1 | – | Sell |
-1,963
| Closed | -$244K | – | 628 |
|
|
2021
Q4 | $244K | Sell |
1,963
-5,567
| -74% | -$729K | ﹤0.01% | 582 |
|
|
2021
Q3 | $1.07M | Sell |
7,530
-956
| -11% | -$141K | ﹤0.01% | 513 |
|
|
2021
Q2 | $1.32M | Buy |
8,486
+62
| +0.7% | +$10K | 0.01% | 502 |
|
|
2021
Q1 | $1.31M | Buy |
+8,424
| New | +$1.3M | 0.01% | 501 |
|
|
2020
Q4 | – | Sell |
-9,126
| Closed | -$1.18M | – | 680 |
|
|
2020
Q3 | $1.18M | Sell |
9,126
-446
| -5% | -$58.3K | 0.01% | 471 |
|
|
2020
Q2 | $1.09M | Sell |
9,572
-16,708
| -64% | -$1.93M | 0.01% | 485 |
|
|
2020
Q1 | $3.24M | Buy |
26,280
+12,225
| +87% | +$1.6M | 0.02% | 408 |
|
|
2019
Q4 | $2.04M | Sell |
14,055
-5,368
| -28% | -$741K | 0.01% | 507 |
|
|
2019
Q3 | $2.59M | Sell |
19,423
-1,642
| -8% | -$212K | 0.01% | 487 |
|
|
2019
Q2 | $2.41M | Sell |
21,065
-22,357
| -51% | -$2.62M | 0.01% | 492 |
|
|
2019
Q1 | $5.38M | Sell |
43,422
-2,754
| -6% | -$313K | 0.03% | 400 |
|
|
2018
Q4 | $4.65M | Sell |
46,176
-128,378
| -74% | -$14.4M | 0.03% | 399 |
|
|
2018
Q3 | $22.3M | Sell |
174,554
-11,077
| -6% | -$1.32M | 0.11% | 239 |
|
|
2018
Q2 | $20.1M | Sell |
185,631
-17,246
| -9% | -$1.88M | 0.11% | 233 |
|
|
2018
Q1 | $21.5M | Sell |
202,877
-20,093
| -9% | -$2.33M | 0.12% | 234 |
|
|
2017
Q4 | $26.2M | Sell |
222,970
-28,635
| -11% | -$3.24M | 0.14% | 215 |
|
|
2017
Q3 | $28.8M | Sell |
251,605
-108,824
| -30% | -$12.6M | 0.16% | 211 |
|
|
2017
Q2 | $44.9M | Sell |
360,429
-40,655
| -10% | -$4.82M | 0.27% | 136 |
|
|
2017
Q1 | $47.5M | Sell |
401,084
-152,116
| -27% | -$17.2M | 0.3% | 101 |
|
|
2016
Q4 | $55.4M | Sell |
553,200
-49,945
| -8% | -$5.35M | 0.36% | 84 |
|
|
2016
Q3 | $76.1M | Buy |
603,145
+128,880
| +27% | +$15.9M | 0.52% | 50 |
|
|
2016
Q2 | $55.4M | Sell |
474,265
-21,314
| -4% | -$2.41M | 0.38% | 76 |
|
|
2016
Q1 | $51.3M | Sell |
495,579
-48,638
| -9% | -$4.71M | 0.36% | 89 |
|
|
2015
Q4 | $54.2M | Sell |
544,217
-57,814
| -10% | -$5.66M | 0.36% | 92 |
|
|
2015
Q3 | $54.9M | Sell |
602,031
-35,492
| -6% | -$3.56M | 0.38% | 83 |
|
|
2015
Q2 | $67.6M | Sell |
637,523
-49,327
| -7% | -$5.46M | 0.38% | 93 |
|
|
2015
Q1 | $78.4M | Sell |
686,850
-76,350
| -10% | -$8.71M | 0.45% | 67 |
|
|
2014
Q4 | $84M | Sell |
763,200
-27,298
| -3% | -$2.88M | 0.48% | 61 |
|
|
2014
Q3 | $77.2M | Buy |
790,498
+75,633
| +11% | +$7.44M | 0.44% | 73 |
|
|
2014
Q2 | $72.1M | Buy |
714,865
+107,597
| +18% | +$10.5M | 0.39% | 85 |
|
|
2014
Q1 | $55.8M | Buy |
607,268
+81,137
| +15% | +$7.48M | 0.31% | 110 |
|
|
2013
Q4 | $47.7M | Buy |
526,131
+123,719
| +31% | +$10.7M | 0.27% | 132 |
|
|
2013
Q3 | $32.2M | Buy |
402,412
+117,907
| +41% | +$9.28M | 0.16% | 179 |
|
|
2013
Q2 | $20.7M | Buy |
+284,505
| New | +$21.3M | 0.14% | 221 |
|
Other funds holding ZBH
Eagle Asset Management's ZBH Position: Q4 2023 in Review
Eagle Asset Management sold out of Zimmer Biomet (ZBH) in Q4 2023, closing a stake of 16,815 shares — an estimated $1.89M sold.
Eagle Asset Management first reported a position in ZBH in Q2 2013 and held it in 36 quarters. The position peaked at $84M in Q4 2014. 1,030 funds tracked by Wall St. Rank hold ZBH as of Q4 2023.
- Eagle Asset Management reported no remaining Zimmer Biomet position as of Q4 2023 after selling out during the quarter.
- Eagle Asset Management sold 16,815 Zimmer Biomet shares in Q4 2023, an estimated $1.89M.
- Eagle Asset Management first reported a position in Zimmer Biomet in Q2 2013 and held it in 36 quarters.
- Eagle Asset Management's Zimmer Biomet position peaked at $84M in Q4 2014.
- 1,030 funds tracked by Wall St. Rank held Zimmer Biomet as of Q4 2023.
Based on Eagle Asset Management's 13F filing for Q4 2023, filed 12 Feb 2024.